Eisai Divests U.S., Puerto Rico Zonegran Rights To Concordia
This article was originally published in PharmAsia News
Executive Summary
Eisai has divested U.S. and Puerto Rico marketing and distribution rights to the Zonegran (zonisamide) anti-epilepsy drug to U.S.-based Concordia Pharmaceuticals.